Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

MULTICENTER TRIAL OF NALOXONE IN ALZHEIMERS-DISEASE ANNALS OF NEUROLOGY Henderson, V. W., Roberts, E., Wimer, C., BARDOLPH, E. L., Chui, H. C., DAMASIO, A. R., ESLINGER, P. J., Folstein, M. F., SCHNEIDER, L. S., Teng, E. L., Tune, L. E., Weiner, L. P., Whitehouse, P. J. 1989; 25 (4): 404-406

Abstract

In a double-blind, placebo-controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1-mg or 10-mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.

View details for Web of Science ID A1989U068400012

View details for PubMedID 2653175